Administration of eptifibatide during transfer for primary pci in patients with stemi: Effect on pre-pci timi flow and its correlation with pain-to-therapy time

Journal of Invasive Cardiology

Volumn 21, Issue 3, 2009, Pages 115-120

  Aquilina, Matteo ^a   Varani, Elisabetta ^a   Balducelli, Marco ^a   Vecchi, Giuseppe ^a   Frassineti, Valeria ^a   Maresta, Aleardo ^a  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

Acute myocardial infarction; Eptifibatide; Primary angioplasty

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE DURATION; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION; THORAX PAIN; THROMBUS ASPIRATION; TREATMENT DURATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CHEST PAIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ITALY; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REGIONAL BLOOD FLOW; RETROSPECTIVE STUDIES; STENTS; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649604202     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2004;110:588-636.
2. McNamara RL, Herrin J, Bradley EH, et al. Hospital improvement in time to reper-fusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol 2006;47:45-51.
3. De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004;43:1363-1367.
4. Montalescot G, Barragan P, Wittenberg O, et al. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
5. Gibson CM, Kirtane AJ, Murphy SA et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 2006;152:668-675.
6. Gabriel HM, Oliveira JA, da Silva PC, et al. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: Results of the early ReoPro administration in my-ocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv 2006;68:218-224.
7. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-eleva-tion myocardial infarction. N Engl J Med 2008;358:2205-2217.
8. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA 2001;285:2468-2473.
9. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction; Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618-627.
10. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activitot, heparin and aspirin for acute myocardial infarction. Ann Internal Med 1991;115:256-265.
11. Rakowski T, Zalewski J, Legutko J, et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: A randomized study. Am Heart J 2007;153:360-365.
12. Tardiff BE, Jennings LK, Harrington RA, et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation 2001;104:399-405.
13. Zeymer U, Zahn R, Schiele R, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Results of the randomized integrilin in acute myocardial infarction (IN-TAMI) pilot trial. Eur Heart J 2005;26:1971-1977.
14. Raveendran G, Ting HH, Best PJ, et al. Eptifibatide vs. abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction. Mayo Clin Proc 2007;82:196-202.
15. Gurm HS, Smith DE, Collins JS, et al. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008;51:529-535.
16. Van't Hof AW, Ten Berg J, Heestermans T et al. Pre-Hospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-Time 2): A multicentre, double-blind, randomised controlled trial. Lancet 2008;372:537-546.